miR-98 Modulates Cytokine Production from Human PBMCs in Systemic Lupus Erythematosus by Targeting IL-6 mRNA
Open Access
- 1 December 2019
- journal article
- research article
- Published by Wiley in Journal of Immunology Research
- Vol. 2019, 1-11
Abstract
Objective. There is evidence that interleukin-6 (IL-6) upregulation plays a critical role in immunopathology of systemic lupus erythematosus (SLE). MicroRNA- (miRNA-) 98 was predicted to bind with the 3-untranslated region (3-UTR) of IL-6 gene. We hypothesized miR-98 through its regulation of IL-6 gene expression to influence cytokine production from peripheral blood mononuclear cells (PBMCs) in SLE. Methods. The expression of miR-98 and IL-6 mRNA in the PBMCs of 41 SLE patients and 20 healthy controls (HC) was detected by quantitative reverse transcription PCR (qRT-PCR). The correlations between miR-98 expression and clinical features were evaluated. Luciferase reporter assay was performed to identify miR-98 targets. miR-98 mimics, miR-98 inhibitor, and IL-6 overexpression vector were generated. Cell viability of PBMCs was assessed using MTT assay. Gene expression and protein level were determined by qRT-PCR and Western blotting. TNF-α, IL-8, IL-1β, and IL-10 levels in cultured supernatants were quantified using ELISA. Results. The expression of miR-98 was downregulated in PBMCs of SLE patients, and its expression is negatively associated with IL-6 levels. miR-98 expression was correlated with disease activity, lupus nephritis, and anti-dsDNA antibody. IL-6 mRNA was a target gene of miR-98. IL-6 overexpression promoted the proliferation of PBMCs and increased the levels of TNF-α, IL-8, IL-1β, and IL-10. Those effects were further enhanced by miR-98 inhibitor, while were suppressed by miR-98 mimics. miR-98 regulated the levels of STAT3 phosphorylation via its target gene IL-6. Conclusion. The current study revealed that miR-98 could ameliorate STAT3-mediated cell proliferation and inflammatory cytokine production via its target gene IL-6 in patients with SLE. These results suggest that miR-98 might serve as a potential target for SLE treatment and other IL-6-mediated diseases.
Keywords
Funding Information
- Program from Guangdong Introducing Innovative and Entrepreneurial Teams (2016ZT06S252, A2018071, 201607010145, 2016A030310136)
- Medical Scientific Research Foundation of Guangdong Province of China (2016ZT06S252, A2018071, 201607010145, 2016A030310136)
- Guangzhou Planned Project of Science and Technology (2016ZT06S252, A2018071, 201607010145, 2016A030310136)
- Natural Science Foundation of Guangdong Province (2016ZT06S252, A2018071, 201607010145, 2016A030310136)
This publication has 30 references indexed in Scilit:
- Stat3 promotes IL-10 expression in lupus T cells through trans- activation and chromatin remodelingProceedings of the National Academy of Sciences, 2014
- Clinical immunologyHypomethylation of interleukin 6 correlates with renal involvement in systemic lupus erythematosusCentral European Journal of Immunology, 2014
- Systemic Lupus ErythematosusAnnals of Internal Medicine, 2013
- Immunoserological parameters in SLE: high-avidity anti-dsDNA detected by ELISA are the most closely associated with the disease activityClinical Rheumatology, 2013
- Systemic Lupus ErythematosusNew England Journal of Medicine, 2011
- Cytokines and Their Roles in the Pathogenesis of Systemic Lupus Erythematosus: From Basics to Recent AdvancesJournal of Biomedicine and Biotechnology, 2010
- Rationale for interleukin-6 blockade in systemic lupus erythematosusLupus, 2004
- Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosusArthritis & Rheumatism, 1997
- Derivation of the sledai. A disease activity index for lupus patientsArthritis & Rheumatism, 1992
- The 1982 revised criteria for the classification of systemic lupus erythematosusArthritis & Rheumatism, 1982